StorMagic Introduces the Most Cost-Effective HCI Solution for Edge and SMB Environments
StorMagic®, solving the world’s edge data problems, today announced SvHCI, which combines a hypervisor and virtual networking with the provider’s proven virtual storage technology used by thousands of customers around the world. This full-stack HCI (hyperconverged infrastructure) solution is purpose-built for edge and small to medium-sized business (SMB) environments and includes StorMagic’s in-house 24x7x365 customer support.
According to the 2024 Gartner® Market Guide for Full-Stack Hyperconverged Infrastructure Software, “the 30% of the non-market leading full-stack HCI installed base that exists in 2024 will increase to 60% by 2029.”* StorMagic believes that this is validating the significant and growing appetite for this type of storage and compute architecture in the market in the wake of the significant market churn witnessed this year.
StorMagic’s SvSAN® is depended on for 100% uptime by customers who currently use VMware or Microsoft hypervisors and is the foundation of the new full-stack solution. SvHCI is a software solution that installs directly on new or existing servers and includes a KVM-based hypervisor, advanced virtual networking and SvSAN as the storage software layer. Just like SvSAN, StorMagic SvHCI simplifies operations and delivers high availability for edge and SMBs environments with only two servers, while lowering software costs by up to 62% over VMware.**
“StorMagic SvHCI delivers exactly what our customers and partners are telling us they need to run applications reliably at their edge and SMB sites,” said Dan Beer, chief executive officer, StorMagic. “This solution is founded on the same tried and true SvSAN code we have been delivering to customers for more than a decade with over 50,000 installations around the world. With SvHCI, we’re helping end users transition from costly, overengineered, overprovisioned software running on VMware to our purpose-built and dependable solution, saving them up to 62% on software costs alone.”
Pricing and Availability
Generally available later this summer, SvHCI is priced starting at $2,049 for a one-year subscription for a single server and up to 2 TB of storage. StorMagic has also launched today an SvHCI Global Beta Program through which customers and partners can get early access to the software and test on their own servers. To learn more about SvHCI and apply for the Global Beta Program, click here.
* Source: Gartner, Market Guide for Full-Stack Hyperconverged Infrastructure Software, By Jeffrey Hewitt, Philip Dawson, Julia Palmer, Tony Harvey, 8 April 2024.
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.
**Range of savings is 21% to 62%. Comparisons include SvHCI 1, 3 and 5 year subscription lengths plus maximum storage capacities of 2TB, 6TB, 12TB, 24TB and 48TB. VMware comparisons are for the same subscription length and storage capacity of VMware vSphere Foundation with VMware vSAN and VMware Cloud Foundation with VMware vSAN.
About StorMagic
StorMagic is solving the world’s edge data problems. We help organizations of all types and sizes use, protect and manage their applications and data at and near the edge. Our solutions are easy to implement and maintain, and eliminate downtime to provide value anytime, anywhere. StorMagic’s solutions are simple, reliable and cost-effective, without sacrificing enterprise-class features, for SMBs to Fortune 500 companies with one to thousands of sites.
Join the Conversation
Follow StorMagic on Facebook, Instagram, LinkedIn, and Twitter, and subscribe to our corporate blog and YouTube channel.
StorMagic, SvSAN, SvKMS and SvHCI are trademarks of StorMagic.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240611750413/en/
Contacts
Matter Communications
stormagic@matternow.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom